Dermatofibrosarcoma Protuberans

• CLINICAL_TRIALS trial_result · 2016-07-01
  Clinical Trial Update: Phase II Pazopanib Study in Advanced Dermatofibrosarcomas [Phase 2]

  A Phase II study of pazopanib in advanced dermatofibrosarcoma protuberans was terminated.

• FDA approval · 2015-12-03
  FDA Approved: IMATINIB MESYLATE — Original Application (BluePoint Laboratories)

  FDA approved the original application for Imatinib Mesylate from BluePoint Laboratories (ANDA078340), authorizing a generic version of the c…

• CLINICAL_TRIALS trial_result · 2015-07-30
  Clinical Trial Update: AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]

  A Phase 2 trial evaluating saracatinib (AZD0530) in adults with recurrent, locally advanced, or metastatic soft tissue sarcoma has completed…

• CLINICAL_TRIALS trial_result · 2013-02-28
  Clinical Trial Update: Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans [Phase 2]

  Phase 2 trial evaluating imatinib mesylate in patients with locally recurrent or metastatic dermatofibrosarcoma protuberans.

• FDA approval · 2013-01-25
  FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis, reflecting changes to the product labeling.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2012-09-24
  Clinical Trial Update: Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma [Phase 2]

  A Phase 2 study evaluating imatinib mesylate in patients with locally advanced or metastatic dermatofibrosarcoma protuberans or giant cell f…

• CLINICAL_TRIALS trial_result · 2012-03-29
  Clinical Trial Update: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans [Phase 2]

  A Phase 2 neoadjuvant trial of imatinib in dermatofibrosarcoma protuberans completed, with results posted in 2012.

• CLINICAL_TRIALS trial_result · 2011-07-29
  Clinical Trial Update: Imatinib in Dermatofibrosarcoma Protuberans (DFSP) [Phase 1, Phase 2]

  Phase 1/2 trial of imatinib for dermatofibrosarcoma protuberans has completed.

• FDA approval · 2008-12-19
  FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis Pharmaceuticals Corporation, resulting in regulatory a…

• FDA approval · 2007-09-13
  FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA supplemental application submitted for GLEEVEC (imatinib mesylate) by Novartis Pharmaceuticals Corporation.

• FDA approval · 2006-10-19
  FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.